Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Snap Inc — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Snap Inc trades at $6.04 (market cap $10.98B). The key difference: Snap Inc is far larger — about 2.1× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Snap Inc for 68 Days on average.
| ORKA | SNAP | |
|---|---|---|
Market Cap | $5.18B | $10.98B |
Volume | 490,798 | 53,140,165 |
Sector | Health | Media |
52-Week High | $113.08 | $9.09 |
52-Week Low | $26.19 | $3.93 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $4.31B | $12.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Snap Inc. (SNAP) trades at $6.49, down 0.76% on the day, showing continued volatility amid mixed signals. The stock maintains a bullish technical outlook with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, revenue growth continues (2025: $5.93B) while losses narrow (net margin improved to -7.77% in 2025), with recent enterprise partnerships for AR glasses driving optimism. Analyst consensus is mixed with 38% buy ratings but a $7.91 price target suggesting 22% upside potential from current levels.
Snap presents a turnaround story with improving operational metrics but significant execution risks. The company's expanding AR/enterprise initiatives and declining losses offer potential upside, though profitability remains elusive and debt levels are substantial. Regulatory pressures and intense social media competition create headwinds. The stock appears fairly valued with a P/S of 1.73, but requires sustained user growth and monetization improvements to justify higher multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
